MedTrace Logo

Pharmacokinetic Drug Interaction Study Following Co-administration of Valsartan, Hydrochlorothiazide and Amlodipine in Patients With Hypertension

NCT00548067 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 111

Last updated 2010-09-27

No results posted yet for this study

Summary

The purpose of this study is to determine potential pharmacokinetic drug-drug interaction when three drugs (valsartan, amlodipine, and hydrochlorothiazide) are co-administered.

Conditions

Interventions

DRUG

Valsartan/hydrochlorothiazide (HCTZ)

DRUG

Valsartan/amlodipine

DRUG

Amlodipine/hydrochlorothiazide(HCTZ)

DRUG

Valsartan/amlodipine/hydrochlorothiazide(HCTZ)

Sponsors & Collaborators

Principal Investigators

  • Novartis · Novartis investigative site

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-09-30
Completion
2008-03-31

Countries

  • India

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00548067 on ClinicalTrials.gov